Restarting CGRPs for Migraine May Lower Response Rate : vima

Restarting a CGRP monoclonal antibody (mAb) after a gap in treatment may lower response rate, a new study suggests. However, switching to a different mAb may counter this effect.

Related Keywords

Madrid , Spain , Barcelona , Comunidad Autonoma De Cataluna , Alicia Gonzalez Martinez , Lars Edvinsson , Alex Jaimes , University Hospital , European Headache Congress , Lund University Hospital Sweden , Hospital Universitario De La Princesa , Hospital Sweden , Medscape Medical , Migraine Headache , Hospitals , Monoclonal Antibody , Etuximab , Ituximab , Europe , European , Receptors , Headache , Adverse Effects , Side Effects , Clinical Guidelines , Guidelines , Clinical Research , Clinical Trials , Linical Studies , Pre Clinical Trial , Double Blind Study , Double Blind Studies , Ingle Blind Study , Ingle Blind Studies , Nonsteroidal Anti Inflammatory Drugs , Nsaids , Said ,